IMs expressing Cxcl13, Cxcl9, and Cxcl10 enhance anti-tumor immunity by promoting TLS formation and lymphocyte recruitment28, 29, 30, whereas Ccl2-expressing IMs recruit recMacs, which in turn drive tumor progression through secretion of pro-tumorigenic mediators. Here, CCL2 is linked to neoplasm.